Suraksha Diagnostic's Profit up by 34% in FY25
By Ankur Chandra | Updated at: May 31, 2025 07:30 PM IST
Kolkata, 28 May 2025 – Suraksha Diagnostic Limited (NSE: SURAKSHA, BSE: 544293) has announced the release of its financial results for the year ended 31 March 2025 (FY25). The reports show strong growth and improved profitability.
FY25 Key Financial Highlights (Standalone & Consolidated)
| Particulars | FY25 (₹ million) | FY24 (₹ million) | YoY Growth |
|---|---|---|---|
| Total Income | 2,559.4 | 2,222.6 | 15.2% |
| EBITDA | 850.9 | 736.2 | 15.6% |
| EBITDA Margin (%) | 33.8% | 33.7% | +10 bps |
| Profit After Tax (PAT) | 309.8 | 231.3 | 34.0% |
| PAT Margin (%) | 12.3% | 10.6% | +170 bps |
Q4 FY25 Performance Snapshot
| Particulars | Q4 FY25 | Q4 FY24 | YoY Growth | Q3 FY25 | QoQ Growth |
|---|---|---|---|---|---|
| Total Income | 659.1 | 561.7 | 17.4% | 601.1 | 9.7% |
| EBITDA | 200.1 | 204.5 | -2.2% | 188.6 | 6.1% |
| EBITDA Margin (%) | 30.7% | 37.1% | -640 bps | 31.7% | -100 bps |
| PAT | 71.7 | 63.2 | 13.4% | 59.9 | 19.8% |
| PAT Margin (%) | 11.0% | 11.5% | -50 bps | 10.1% | +90 bps |
Segment Performance and Expansion
- Revenue from Operations for Q4 FY25 rose 18% YoY to ₹651.0 million.
- During FY25, the company added seven diagnostic centres, including one large, one medium, three small, and two PPP centres.
Strategic Acquisition: Fetomat Wellness
In April 2025, Suraksha Diagnostic acquired a controlling stake (approx. 63%) in Fetomat Wellness Private Limited. The primary objective of the acquisition was to initiate operations in genomic medicine. Fetomat Wellness specialises in pregnancy care, prenatal diagnostics, genetic counselling, and medical training and is expected to help improve Suraksha’s core diagnostics operations.
Management Commentary
Ritu Mittal, Joint Managing Director & CEO, stated:
“We are pleased to present our first full-year financial results post-listing, marking a strong performance with revenue growing 15.3% and PAT increasing 34%. Despite headwinds like a doctors’ strike and the Bangladesh issue, we stayed on course with expansion. The Fetomat acquisition positions us at the frontier of genomic diagnostics. We expect further margin improvement as new centers mature and throughput increases.”
Strategic Outlook
In FY26, the company:
- Plans to add 15–18 centres.
- Focus on areas such as higher throughput, cost optimisation, and margin expansion.
About the Company
Suraksha Diagnostic Limited is an Indian company that operates diagnostic services in Eastern India, such as pathology, radiology, and consultation services. The company was established in 2005 and also offers online medical consultation services.
Reference: https://nsearchives.nseindia.com/corporate/SURAKSHA_28052025233026_Suraksha_Press_release_Q4__FY_2024_25.pdf
